
uniQure julkisti päivityksen AMT-130-geeniterapian vaiheen I/II kliinisistä tutkimuksista Huntingtonin taudin hoidossa.
~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural history of the disease ~ ~ Mean